Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2010

Open Access 01-12-2010 | Research

Diabetes-related molecular signatures in infrared spectra of human saliva

Authors: David A Scott, Diane E Renaud, Sathya Krishnasamy, Pinar Meriç, Nurcan Buduneli, Şvetki Çetinkalp, Kan-Zhi Liu

Published in: Diabetology & Metabolic Syndrome | Issue 1/2010

Login to get access

Abstract

Background

There is an ongoing need for improvements in non-invasive, point-of-care tools for the diagnosis and prognosis of diabetes mellitus. Ideally, such technologies would allow for community screening.

Methods

In this study, we employed infrared spectroscopy as a novel diagnostic tool in the prediction of diabetic status by analyzing the molecular and sub-molecular spectral signatures of saliva collected from subjects with diabetes (n = 39) and healthy controls (n = 22).

Results

Spectral analysis revealed differences in several major metabolic components - lipid, proteins, glucose, thiocyanate and carboxylate - that clearly demarcate healthy and diseased saliva. The overall accuracy for the diagnosis of diabetes based on infrared spectroscopy was 100% on the training set and 88.2% on the validation set. Therefore, we have established that infrared spectroscopy can be used to generate complex biochemical profiles in saliva and identify several potential diabetes-associated spectral features.

Conclusions

Infrared spectroscopy may represent an appropriate tool with which to identify novel diseases mechanisms, risk factors for diabetic complications and markers of therapeutic efficacy. Further study into the potential utility of infrared spectroscopy as diagnostic and prognostic tool for diabetes is warranted.
Appendix
Available only for authorised users
Literature
1.
A.D.A.: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007, 30 (Suppl 1): S42-47.
2.
Standards of medical care in diabetes. Diabetes Care. 2007, 30 (Suppl 1): S4-S41.
3.
Paroni R, Ceriotti F, Galanello R, Battista Leoni G, Panico A, Scurati E, Paleari R, Chemello L, Quaino V, Scaldaferri L, et al: Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. Clin Biochem. 2007, 40 (18): 1398-1405. 10.1016/j.clinbiochem.2007.08.001.PubMed
4.
Picardi A, Pozzilli P: Dynamic tests in the clinical management of diabetes. J Endocrinol Invest. 2003, 26 (7 Suppl): 99-106.PubMed
5.
Wallace TM, Matthews DR: Recent advances in the monitoring and management of diabetic ketoacidosis. Qjm. 2004, 97 (12): 773-780. 10.1093/qjmed/hch132.PubMed
6.
Caramori ML, Fioretto P, Mauer M: Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol. 2006, 17 (2): 339-352. 10.1681/ASN.2005101075.PubMed
7.
Macisaac RJ, Tsalamandris C, Thomas MC, Premaratne E, Panagiotopoulos S, Smith TJ, Poon A, Jenkins MA, Ratnaike SI, Power DA, et al: The accuracy of cystatin C and commonly used creatinine-based methods for detecting moderate and mild chronic kidney disease in diabetes. Diabet Med. 2007, 24 (4): 443-448. 10.1111/j.1464-5491.2007.02112.x.PubMed
8.
Wasserfall CH, Atkinson MA: Autoantibody markers for the diagnosis and prediction of type 1 diabetes. Autoimmun Rev. 2006, 5 (6): 424-428. 10.1016/j.autrev.2005.12.002.PubMed
9.
Seissler J, Scherbaum WA: Autoimmune diagnostics in diabetes mellitus. Clin Chem Lab Med. 2006, 44 (2): 133-137. 10.1515/CCLM.2006.025.PubMed
10.
Cameron NE, Cotter MA: Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets. 2008, 9 (1): 60-67. 10.2174/138945008783431718.PubMed
11.
Aronson D: Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Med Hypotheses. 2002, 59 (3): 297-301. 10.1016/S0306-9877(02)00172-X.PubMed
12.
Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988, 318 (20): 1315-1321. 10.1056/NEJM198805193182007.PubMed
13.
Aydin S: A comparison of ghrelin, glucose, alpha-amylase and protein levels in saliva from diabetics. J Biochem Mol Biol. 2007, 40 (1): 29-35.PubMed
14.
Belazi MA, Galli-Tsinopoulou A, Drakoulakos D, Fleva A, Papanayiotou PH: Salivary alterations in insulin-dependent diabetes mellitus. Int J Paediatr Dent. 1998, 8 (1): 29-33. 10.1046/j.1365-263X.1998.00057.x.PubMed
15.
Borg Andersson A, Birkhed D, Berntorp K, Lindgarde F, Matsson L: Glucose concentration in parotid saliva after glucose/food intake in individuals with glucose intolerance and diabetes mellitus. Eur J Oral Sci. 1998, 106 (5): 931-937. 10.1046/j.0909-8836.1998.eos106505.x.PubMed
16.
Miedema K: Laboratory tests in diagnosis and management of diabetes mellitus. Practical considerations. Clin Chem Lab Med. 2003, 41 (9): 1259-1265. 10.1515/CCLM.2003.193.PubMed
17.
Yoon MS, Jankowski V, Montag S, Zidek W, Henning L, Schluter H, Tepel M, Jankowski J: Characterisation of advanced glycation endproducts in saliva from patients with diabetes mellitus. Biochem Biophys Res Commun. 2004, 323 (2): 377-381. 10.1016/j.bbrc.2004.08.118.PubMed
18.
Zloczower M, Reznick AZ, Zouby RO, Nagler RM: Relationship of flow rate, uric acid, peroxidase, and superoxide dismutase activity levels with complications in diabetic patients: can saliva be used to diagnose diabetes?. Antioxid Redox Signal. 2007, 9 (6): 765-773. 10.1089/ars.2007.1515.PubMed
19.
Liu KZ, Dembinski TC, Mantsch HH: Rapid determination of fetal lung maturity from infrared spectra of amniotic fluid. Am J Obstet Gynecol. 1998, 178 (2): 234-241. 10.1016/S0002-9378(98)80006-9.PubMed
20.
Haas SL, Muller R, Fernandes A, Dzeyk-Boycheva K, Wurl S, Hohmann J, Hemberger S, Elmas E, Bruckmann M, Bugert P, et al: Spectroscopic diagnosis of myocardial infarction and heart failure by Fourier transform infrared spectroscopy in serum samples. Appl Spectrosc. 2010, 64 (3): 262-267. 10.1366/000370210790918508.PubMed
21.
Staib A, Dolenko B, Fink DJ, Fruh J, Nikulin AE, Otto M, Pessin-Minsley MS, Quarder O, Somorjai R, Thienel U, et al: Disease pattern recognition testing for rheumatoid arthritis using infrared spectra of human serum. Clin Chim Acta. 2001, 308 (1-2): 79-89. 10.1016/S0009-8981(01)00475-2.PubMed
22.
Peuchant E, Richard-Harston S, Bourdel-Marchasson I, Dartigues JF, Letenneur L, Barberger-Gateau P, Arnaud-Dabernat S, Daniel JY: Infrared spectroscopy: a reagent-free method to distinguish Alzheimer's disease patients from normal-aging subjects. Transl Res. 2008, 152 (3): 103-112. 10.1016/j.trsl.2008.05.009.PubMed
23.
Sato K, Seimiya M, Kodera Y, Kitamura A, Nomura F: Application of Fourier-transform infrared (FT-IR) spectroscopy for simple and easy determination of chylomicron-triglyceride and very low density lipoprotein-triglyceride. Clin Chim Acta. 2010, 411 (3-4): 285-290. 10.1016/j.cca.2009.11.026.PubMed
24.
Ansari NA, Alam K, Ali A: Preferential recognition of Amadori-rich lysine residues by serum antibodies in diabetes mellitus: role of protein glycation in the disease process. Hum Immunol. 2009, 70 (6): 417-424. 10.1016/j.humimm.2009.03.015.PubMed
25.
Kiefer J, Obert K, Fries J, Bosmann A, Wasserscheid P, Leipertz A: Determination of glucose and cellobiose dissolved in the ionic liquid 1-ethyl-3-methylimidazolium acetate using Fourier transform infrared spectroscopy. Appl Spectrosc. 2009, 63 (9): 1041-1049. 10.1366/000370209789379367.PubMed
26.
Liu KZ, Tsang KS, Li CK, Shaw RA, Mantsch HH: Infrared spectroscopic identification of beta-thalassemia. Clin Chem. 2003, 49 (7): 1125-1132. 10.1373/49.7.1125.PubMed
27.
Borden JT, Man A, Scott DA, Liu KZ: Tobacco-induced alterations to the Fourier-transform infrared spectrum of serum. J Mol Med. 2003, 81 (12): 788-794. 10.1007/s00109-003-0490-3.PubMed
28.
Liu KZ, Shaw RA, Man A, Dembinski TC, Mantsch HH: Reagent-free, simultaneous determination of serum cholesterol in HDL and LDL by infrared spectroscopy. Clin Chem. 2002, 48 (3): 499-506.PubMed
29.
Schultz CP, Ahmed MK, Dawes C, Mantsch HH: Thiocyanate levels in human saliva: quantitation by Fourier transform infrared spectroscopy. Anal Biochem. 1996, 240 (1): 7-12. 10.1006/abio.1996.0323.PubMed
30.
Pruitt KM, Mansson-Rahemtulla B, Baldone DC, Rahemtulla F: Steady-state kinetics of thiocyanate oxidation catalyzed by human salivary peroxidase. Biochemistry. 1988, 27 (1): 240-245. 10.1021/bi00401a036.PubMed
31.
Ruth KJ, Neaton JD: Evaluation of two biological markers of tobacco exposure. MRFIT Research Group. Prev Med. 1991, 20 (5): 574-589. 10.1016/0091-7435(91)90056-A.PubMed
32.
Karjalainen S, Sewon L, Soderling E, Larsson B, Johansson I, Simell O, Lapinleimu H, Seppanen R: Salivary cholesterol of healthy adults in relation to serum cholesterol concentration and oral health. J Dent Res. 1997, 76 (10): 1637-1643. 10.1177/00220345970760100401.PubMed
33.
Rassi DM, Junta CM, Fachin AL, Sandrin-Garcia P, Mello S, Marques MM, Fernandes AP, Foss-Freitas MC, Foss MC, Sakamoto-Hojo ET, et al: Metabolism genes are among the differentially expressed ones observed in lymphomononuclear cells of recently diagnosed type 1 diabetes mellitus patients. Ann N Y Acad Sci. 2006, 1079: 171-176. 10.1196/annals.1375.026.PubMed
34.
35.
Tabak LA: Point-of-care diagnostics enter the mouth. Ann N Y Acad Sci. 2007, 1098: 7-14. 10.1196/annals.1384.043.PubMed
36.
Jurysta C, Bulur N, Oguzhan B, Satman I, Yilmaz TM, Malaisse WJ, Sener A: Salivary glucose concentration and excretion in normal and diabetic subjects. Journal of Biomedicine & Biotechnology. 2009, 2009: 430426-
37.
Darwazeh AM, MacFarlane TW, McCuish A, Lamey PJ: Mixed salivary glucose levels and candidal carriage in patients with diabetes mellitus. Journal of Oral Pathology & Medicine. 1991, 20 (6): 280-283.
38.
Garay-Sevilla ME, Regalado JC, Malacara JM, Nava LE, Wrobel-Zasada K, Castro-Rivas A, Wrobel K: Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with type 2 diabetes mellitus. Journal of Endocrinological Investigation. 2005, 28 (3): 223-230.PubMed
39.
Sola-Penna M: Metabolic regulation by lactate. IUBMB Life. 2008, 60 (9): 605-608. 10.1002/iub.97.PubMed
40.
Balkau B, Forhan A, Simon D, Eschwege E: HbA1c as a diagnostic tool for diabetes. International Congress Series. 2003, 1253: 19-26. 10.1016/S0531-5131(03)00540-5.
41.
Cassiday L: Nothing to spit at: the salivary proteome of type 2 diabetes. J Proteome Res. 2009, 8 (1): 3-10.1021/pr8008397.PubMed
Metadata
Title
Diabetes-related molecular signatures in infrared spectra of human saliva
Authors
David A Scott
Diane E Renaud
Sathya Krishnasamy
Pinar Meriç
Nurcan Buduneli
Şvetki Çetinkalp
Kan-Zhi Liu
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2010
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-2-48

Other articles of this Issue 1/2010

Diabetology & Metabolic Syndrome 1/2010 Go to the issue

Letter to the Editor

Conjugated Linoleic Acid: good or bad nutrient

Research

Is exercise a therapeutic tool for improvement of cardiovascular risk factors in adolescents with type 1 diabetes mellitus? A randomised controlled trial

Research

Prevalence of Metabolic Syndrome and its influence on microvascular complications in the Indian population with Type 2 Diabetes Mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular Genetic Study (SN-DREAMS, report 14)

Commentary

Evaluation of major depression in a routine clinical assessment

Research

Influence of muscle fitness test performance on metabolic risk factors among adolescent girls

Short report

Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits